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ABSTRACT 
 
 
The high prevalence of metabolic syndrome in children is mainly due to the adoption of an 
unhealthy diet and a sedentary lifestyle.
 
The disorder is also associated with obesity, insulin 
resistance, hypertension and increased blood levels of triglycerides, free fatty acids and 
glucose. Although metabolic syndrome and its metabolic complications can be managed by 
the use of conventional medicines such as fenofibrate and metformin, there is a growing use of 
plants with medicinal properties.  Aloe vera has been used for several medicinal purposes such 
as wound and burn healing, treatment of diabetes and treatment of cancer. Aloe vera also has 
biological activities that include anti-inflammatory, anti-microbial and laxative effects.  
Previous studies exploring the metabolic effects of Aloe vera have been in adult animals where 
metabolic syndrome was induced by the use of pharmacological agents. However, its 
beneficial effects in growing children who are at risk of developing metabolic syndrome have 
not been fully explored.  
The objectives of this study were to evaluate the effects of a crude Aloe vera leaf extract on 
circulating metabolic substrates, the morphometry and morphology of the gastrointestinal tract 
and the liver function of growing rats.  
Fifty-nine male Sprague-Dawley rats of 21 days old were randomly divided into one of six 
treatment groups. Group I (control) was fed normal rat chow (NRC) with plain gelatine cubes 
(vehicle). Group II received a high carbohydrate diet (HCD) with plain gelatine cubes; Group 
III received normal rat chow and fenofibrate at 100mg.kg
-1
; Group IV received a HCD and 
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fenofibrate at 100mg.kg
-1
; Group V received a normal rat chow and Aloe vera at 300mg.kg
-1
; 
Group VI received a HCD and Aloe vera at 300mg.kg
-1
. The Aloe vera and fenofibrate were 
suspended in  gelatine cubes and administered daily. After 20 weeks of feeding, the rats were 
fasted over night and an oral glucose tolerance test (OGTT) was performed. The rats were then 
euthanazed after 48 hours of re-feeding and tissues were collectedfor further analysis.  The 
data was expressed as mean ± SEM and analyzed by a one-way ANOVA. A repeated 
measures ANOVA was used for statistical analysis of the data from the oral glucose tolerance 
test. The values were considered statistically significant when p < 0.05 followed by a 
Bonferroni Post hoc test.  
After 20 weeks, the growing rats fed a high carbohydrate diet had a significantly higher body 
mass than the other groups (p < 0.05, ANOVA), however the administration of fenofibrate 
prevented the high carbohydrate-induced increase in body mass whilst Aloe vera was not 
effective. Linear growth as measured by the tibial length was not significantly different 
between the groups (p >0.05, ANOVA). There was no significant difference in the mass and 
relative density of the tibia bones of the rats between the groups. Feeding rats a HCD resulted 
in a higher (p< 0.05, ANOVA) visceral fat mass in the rats. Fenofibrate administration 
prevented the HCD-induced visceral fat mass gain whilst Aloe vera administration had no 
effect. Whilst the treatments did not result in any significant differences in the lengths and 
mass of the small intestine, the mass of the large intestine was significantly lower in the rats 
that received the HCD alone (p < 0.05, ANOVA). Fenofibrate administration resulted in a 
significantly increased liver mass compared to the other groups (p < 0.05, ANOVA). However 
there was no significant difference in the lipid and glycogen content in the liver.    
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Fasting concentrations of metabolic substrates (glucose, triglycerides and free fatty acids) 
were not significantly different between the groups and no significant differences were 
observed in the circulating concentrations of insulin and the homeostasis model assessment of 
insulin resistance (HOMA-IR) (ANOVA; p>0.05). The OGTT did not show any abnormalities 
in the ability of the rats to handle a glucose load between the groups. 
An indirect assessment of liver function was performed by measurements of the blood 
concentrations of alkaline phosphatase (ALP), total bilirubin (TBIL), alkaline transaminase 
(ALT) and gamma-glutamyl transferase (GGT). There were significantly increased (p<0.05) 
ALP levels in rats fed NRC + FENO compared to the others. TBIL levels were significantly 
lower in rats fed a NRC + Av (p< 0.05, ANOVA) however the TBIL levels were within the 
normal range. The alkaline transaminase (ALT) levels were not significantly different between 
the groups (p < 0.05, ANOVA) and GGT was not detectable in any of the groups.   
Weaning rats onto a high carbohydrate diet and feeding them the diet for 20 weeks resulted in 
the development of visceral obesity without altering the glucose tolerance and metabolic 
substrates. The treatment with fenofibrate prevented the high carbohydrate diet-induced 
visceral adiposity however compared to fenofibrate, treatment with the Aloe vera leaf 
preparation was not significantly effective. 
 
 
 
ix 
 
TABLE OF CONTENT 
DECLARATION .......................................................................................................................... i 
CONFERENCE PRESENTATIONS ......................................................................................... ii 
DEDICATION .......................................................................................................................... iii 
ACKNOWLEDGEMENTS ....................................................................................................... iv 
ABSTRACT ............................................................................................................................... vi 
TABLE OF CONTENT ............................................................................................................. ix 
LIST OF FIGURES ................................................................................................................. xiii 
LIST OF TABLES ................................................................................................................... xiv 
LIST OF ABBREVIATIONS ................................................................................................... xv 
CHAPTER ONE- INTRODUCTION ......................................................................................... 1 
1.0. Preface .............................................................................................................................. 2 
1.1 Introduction ........................................................................................................................... 3 
1.1.1. Insulin release ............................................................................................................ 3 
1.1.2. Consequences of metabolic syndrome ...................................................................... 5 
1.1.2.1. Complications of diabetes .................................................................................. 6 
1.1.3. Fenofibrate ................................................................................................................ 8 
1.1.4. Aloe vera ................................................................................................................... 9 
x 
 
1.1.4.1. Classification ................................................................................................... 10 
1.1.4.2. Structural composition and bioactive chemical constituents ........................... 12 
1.1.4.3. Therapeutic uses of Aloe vera .......................................................................... 15 
1.1.5. Gastrointestinal system ........................................................................................... 17 
1.1.6. Justification of the study ......................................................................................... 19 
1.1.7. Aims of the study .................................................................................................... 20 
CHAPTER TWO-MATERIALS AND METHODS ................................................................. 22 
2.1. Study setting ................................................................................................................... 23 
2.1.1. Ethical approval....................................................................................................... 23 
2.1.2. Experimental design ................................................................................................ 23 
2.2. Materials ......................................................................................................................... 24 
2.2.1. Plant collection ........................................................................................................ 24 
2.3. Methods .......................................................................................................................... 25 
2.3.1. Preparation of Aloe vera leaf extracts ..................................................................... 25 
2.3.2. Feeds........................................................................................................................ 25 
2.3.3. Housing of animals.................................................................................................. 26 
2.4. Analytical procedures ..................................................................................................... 27 
2.4.1. Body mass ............................................................................................................... 27 
xi 
 
2.4.2. Oral glucose tolerance test (OGTT) and measurement of fasting metabolic 
substrates (triglycerides (TGs) and glucose) ......................................................................... 27 
2.5. Terminal Procedures ....................................................................................................... 28 
2.5.1. Blood sampling and plasma processing .................................................................. 28 
2.5.2. Visceral measurements and histology ..................................................................... 29 
2.5.3. Determination of liver lipid content ........................................................................ 29 
2.5.4. Determination of hepatic glycogen content ............................................................ 30 
2.5.5. Tibia lengths and masses ......................................................................................... 31 
2.5.6. Plasma free fatty acid concentrations ...................................................................... 31 
2.5.7. Measurement of liver enzymes and total bilirubin in serum ................................... 32 
2.5.8. Insulin measurements .............................................................................................. 33 
2.5.9. Statistical analysis ................................................................................................... 34 
CHAPTER THREE-RESULTS ................................................................................................ 35 
3.1. Mortality and morbidity of the animals .............................................................................. 36 
3.2. The effects of Aloe vera leaf extract on body mass gain .................................................... 36 
3.3. The effect of Aloe vera leaf extract on the linear growth (tibia) ........................................ 38 
3.4. The effect of Aloe vera leaf extract on circulating insulin and metabolic substrates ......... 40 
3.5. Effects of Aloe vera leaf extract on abdominal visceral organ morphometry and 
morphology…………………………………………………………………… ........................ 42 
xii 
 
3.5. The effect of Aloe vera leaf extract on the response to an oral glucose load ..................... 49 
3.7. The effect of Aloe vera leaf extract on liver enzymes and total bilirubin .......................... 51 
3.8. The effect of Aloe vera leaf extract on hepatic lipid and glycogen content ....................... 54 
CHAPTER FOUR- DISCUSSION ........................................................................................... 57 
CHAPTER FIVE- CONCLUSION AND RECOMENDATIONS ........................................... 65 
CHAPTER SIX-REFERENCES ............................................................................................... 68 
APPENDIX ............................................................................................................................... 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF FIGURES   
Figure 1.1 Insulin secretion in the beta cell triggered by an increase in blood glucose levels. ... 4 
Figure 1.2 Aloe  vera plant ........................................................................................................ 11 
Figure 1.3 Aloe vera plant and the bioactive chemical constituents……………..……………12 
Figure 3.1 Effect of Aloe vera leaf extract on body mass gain ................................................. 37 
Figure 3.2 Effect of Aloe vera leaf extract on visceral fat mass ................................................ 43 
Figure 3.3 Effect of Aloe vera leaf extract on the liver mass .................................................... 44 
Figure 3.4 Effects of Aloe vera leaf extract on the response to an oral glucose load ................ 50 
Figure 3.5 Effect of Aloe vera leaf extract on hepatic lipid content of growing rats ................ 55 
Figure 3.6 Effect of Aloe vera leaf extract on hepatic glycogen content of growing rats ......... 56 
                                                                                            
 
 
 
 
 
 
 
xiv 
 
LIST OF TABLES                                                                                                                    
 
 
Table 1.1: Bioactive chemical constituents of Aloe vera. ......................................................... 13 
Table 3.1 Effect of Aloe vera leaf extract on the length and mass of the tibias of growing rats.
 ................................................................................................................................................... 39 
Table 3.2: Effect of Aloe vera leaf extract on fasting concentrations of metabolic substrates 
and circulating insulin. .............................................................................................................. 41 
Table 3.3: Effect of Aloe vera leaf extract on the absolute mass (g) and the mass (% relative to 
tibia length) of the viscera and, length (mm) of GIT segments of growing rats. ...................... 45 
Table 3.4: Effect of a crude Aloe vera leaf extract on microscopic measurements of small 
intestine in growing rats. ........................................................................................................... 48 
Table 3.5: Effect of Aloe vera extract on the liver enzymes (ALT, ALP and GGT) and total 
bilurubin of the growing rats. .................................................................................................... 52 
 
 
 
 
 
 
 
xv 
 
 
LIST OF ABBREVIATIONS 
AESC                                                                Animal Ethics Screening Committee 
ALT                                                                      Alanine-amino Transferase                                                                                                                                                                                                        
ANOVA                                                                Analysis of variance 
Av                                                                         Aloe vera                                                                                                                               
ALP                                                                     Alkaline Phosphatase                                                                                                           
BM                                                                       Body mass                                                                                                                            
DM                                                                       Diabetes mellitus                                                                                                                  
FENO                                                                   Fenofibrate                                                                                                                            
FFAs                                                                    Free fatty acids 
GGT                                                                     Gamma-glutamyl transferase                                                                                                                          
GLUTs                                                                 Glucose transporters                                                                                                                                                                                                                                   
HCD                                                                     High carbohydrate diet                                                                                                         
                                                                                                                
NRC                                                                      Normal rat chow                                                                                                                     
OGTT                                                                   Oral Glucose Tolerance Test                                                                                                 
xvi 
 
PPAR- α                                                                Peroxisome proliferator activated receptor 
alpha                                                                  
NaOH                                                                    Sodium hydroxide 
TBIL                                                                      Total bilirubin                                           
TGs                                                                       Triglycerides                                                                                                                          
TIDM                                                                    Type I diabetes mellitus                                                                                                         
TIIDM                                                                   Type II diabetes mellitus                                                                                                        
WHO                                                                     World Health Organization                                                                                                     
1 
 
 
 
 
 
CHAPTER ONE- INTRODUCTION  
 
 
 
 
 
 
 
 
2 
 
1.0. Preface 
Metabolic syndrome is a disorder characterized by several risk factors including obesity, 
insulin resistance and diabetes mellitus (DM). There is a resultant chronic increased glucose 
blood level (hyperglycaemia) due to a lack/reduction in insulin action. The disorder is also 
associated with hypertension, increased blood levels of triglycerides and free fatty acids.  
Obesity is mainly caused by a lack of exercise or excess consumption of diets that are rich in 
refined sugars and fats. Unfortunately, the prevalence of obesity and its complications is 
increasing in children. Despite the use of conventional drugs such as fenofibrate, 
antihypertensives, statins and metformin for the management of the metabolic syndrome 
associated with obesity, the management of obesity related metabolic syndrome in many 
communities also includes the use of several medicinal plants. Among these plants, Aloe vera 
is commonly used as herbal medicine in many cultures. Aloe vera has been shown to have 
antidiabetic effects through mechanisms that are yet to be fully explored. It has been 
previously reported that the anti-diabetic effects of Aloe vera in streptozotocin (STZ)-induced 
diabetic rats is mediated through the presence of glucomannans and phytosterols which 
decrease serum cholesterol. The current study aimed to establish an animal based model of 
diet-induced metabolic dysfunction and to investigate whether dietary supplementation with 
Aloe vera delayed the development of diet-induced metabolic dysfunction in growing rats. In 
an effort to fully understand the possible  mechanism(s) of action of Aloe vera the study  
explored some of  the regulatory mechanisms by which Aloe vera could modify dietary-
induced metabolic dysfunction in growing  rats by focusing on metabolically active tissues, 
namely the liver and adipose tissue. Chapter 1 describes the physiology of insulin release, 
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consequences of metabolic dysfunction, pharmacology and some general therapeutic effects of 
Aloe vera. The aims, the objectives and justification for the study are also included in this 
introductory chapter. 
 
1.1 Introduction 
Metabolic syndrome a lifestyle disease, is a common metabolic disorder characterized by a 
group of metabolic risk factors, the five risk factors are visceral obesity, dyslipidemia (≥3.87 
mmol.L
-1
 triglycerides in circulation) with fatty liver due to accumulation of triglycerides in 
the liver, lower than normal HDL cholesterol, elevated fasting blood glucose (≥ 4 mmol. L-1) 
and High blood pressure (Ker et al., 2007). In 2008, over 1.4 billion adults (20 years and 
older) were overweight and over 500 million were obese. The number of overweight children 
below the age of five was estimated to be over 42 million in 2010 (WHO) and 35 million of 
these were in developing countries such as South Africa (Rossouw et al.,2012). 
The high prevalence of childhood obesity is mainly due to the adoption of an unhealthy diet 
and a sedentary lifestyle (Slyper, 2004). Metabolic risk factors that develop due to the 
consumption of a high carbohydrate diet are strongly linked to the rapid release of insulin and 
the development of insulin resistance (McKeown et al., 2004).  
1.1.1. Insulin release  
 
 Under normal conditions, the concentration of blood glucose is maintained within a narrow 
range mainly through metabolic hormones. The hormones include glucagon that plays an 
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essential role when the blood glucose levels are low while the pancreatic β-cell hormone, 
insulin decreases blood glucose levels when they are high. When blood glucose concentrations 
increase after a meal, insulin secretion is triggered. Through facilitated diffusion, glucose is 
transported into pancreatic cells via GLUT-2  causing an increase in the ATP/ADP ratio which 
depolarizes the plasma membrane of the β cells. This causes the ATP-sensitive potassium 
(KATP) channel to close (Figure 1.1), thereby causing an influx in Ca
2+ 
which stimulates insulin 
secretion (Ashcroft and Gribble, 1999). Insulin then enhances glucose uptake by the adipose 
and muscle cells, the target tissues for insulin action where the glucose is converted into 
glycogen and lipids (Shepherd and Kahn, 1999). Insulin release therefore triggers several 
processes that ensure the storage of nutrients via its action on its target cells.  
 
Figure 1.1. Insulin secretion in the beta cell triggered by an increase in blood glucose 
levels (Modified from Beta Cell Biology Consortium, 2004 
www.betacell.org/content/articleview/article_id/1/). 
 
5 
 
The process of insulin secretion described above may be disturbed as a result of excess 
consumption of carbohydrates leading to insulin resistance (Basciano et al., 2005). Insulin 
resistance is a condition wherein the activity of insulin is inadequate to exert an effect on 
insulin receptors in liver and adipose tissues (Ingelsson et al., 2005). Decreased insulin 
sensitivity may result in impaired cellular glucose uptake and an increase in blood glucose 
concentrations. As a result of impaired glucose storage, fat deposition begins to occur around 
visceral organs. Visceral fat deposition is one of the characteristics of insulin resistance and is 
linked with the development of metabolic dysfunction (McKeown et al., 2004). In addition, 
excess consumption of diets rich in carbohydrates may stimulate lipolysis causing an increase 
in blood triglyceride concentrations (Thorbum, 1989). Insulin resistance is strongly linked to 
the development of cardiovascular disease and diabetes mellitus. The following section will 
focus on one of the components of metabolic syndrome, diabetes mellitus. 
   
1.1.2. Consequences of metabolic syndrome 
 
Diabetes mellitus (DM) is a metabolic disorder characterized by increased blood glucose 
levels (hyperglycaemia) (Grover et al., 2002). Hyperglycaemia can be due to a deficiency or 
insulin’s inability to exert its blood glucose lowering effects (Groop, 1992). Diabetes mellitus 
is a major public health problem. An estimated 171 million people were diagnosed with 
diabetes in the year 2010 worldwide. ). The number is expected to grow to 366 million in 2030 
(IDF, Diabetes Atlas, 2012).In 2003, 3.4 % of the 24 million South Africans were diabetic 
with an expected increase to 3.9 % by 2025 (Rheeder P, 2006. There are two common types of 
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DM, type I diabetes mellitus (TIDM) and type II diabetes mellitus (TIIDM). TIDM is an 
autoimmune disease that is caused by the pancreatic β cell’s inability to secrete insulin (Kumar 
and Clark, 2002).  TIDM can affect both adults and children, it was traditionally termed 
“juvenile diabetes” due to its high prevalence in children.   
 The increasing prevalence of diabetes is associated with several factors that include age and 
the rapid increase in metabolic dysfunction or obesity, due to a lack of exercise and the 
adoption of western diets rich in carbohydrates (Chan and Abrahamson, 2003).   Although the 
cause of diabetes is unclear, it involves both an impaired insulin secretion and development of 
insulin resistance. Insulin resistance usually results as a consequence of insulin’s inability to 
exert its effect on insulin receptors which is associated with obesity (mostly occurs in TIIDM). 
The World Health Organization reported that diabetes mellitus was one of the major causes of 
deaths worldwide (WHO, report, 1999). In South Africa, the number of people suffering from 
diabetes has been rising significantly over the years (King et al., 1998). Diabetes is one of the 
leading causes of death that result from long-term exposure to microvascular complications 
(Chan and Abrahamson, 2003).  
1.1.2.1. Complications of diabetes 
 
Hyperglycemia is a common cause of complications in diabetic patients (Reusch, 2003). 
Complications of hyperglycemia are divided into microvascular (nephropathy, neuropathy and 
retinopathy) and macrovascular (myocardial infarction, stroke and peripheral arterial disease) 
(Fowler, 2008). Retinopathy is the most common microvascular complication and may 
develop as early as 7 years before the diagnosis of diabetes in patients with diabetes (Fong et 
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al., 2004). Diabetic retinopathy is caused by damage of the blood vessels in the retina resulting 
in the formation of a blood-retinal barrier, therefore causing blindness (Fowler, 2008). 
Diabetic nephropathy refers to the damage in the kidneys especially in diabetic patients with 
high blood pressure and is the leading cause of renal failure (Wolf, 2004).  
Macrovascular complications are the main cause of morbidity and mortality in diabetic 
patients. Macrovascular diseases are those that damage large blood vessels. Damage can cause 
blood vessels to narrow, which decreases blood supply in areas in need of blood. One of the 
complications is stroke, where the blood supply to the brain and heart is decreased (Sweetnam 
et al., 2012). These complications usually result from disturbances in glucose homeostasis due 
to insulin resistance, which lead to structural changes in different cells such as 
cardiomyocytes, adipocytes and hepatocytes (Burns et al., 1999). Uncomplicated metabolic 
dysfunction can be managed by lifestyle changes such as daily exercise and adopting a healthy 
diet. However, pharmacological intervention is necessary to manage the metabolic dysfunction 
in complicated cases (Chan and Abrahamson, 2003). Treatment methods for metabolic 
dysfunction aim at lowering increased fatty acids and glucose levels back to normal (Li et al., 
2004). Pharmacological agents, such as, fenofibrate, metformin, statins and antihypertensives 
have been used for the treatment of some of the complications of metabolic syndrome. For my 
study, I chose to use fenofibrate as a positive control pharmacological agent for comparison to 
Aloe vera. The following section describes the mechanisms by which fenofibrate exerts its 
action.  
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1.1.3. Fenofibrate 
 
Fenofibrate is a lipid lowering agent and is mainly used to reduce cholesterol in patients that 
are at risk of developing cardiovascular disease. Fenofibrate is a fibric acid derivative whose 
effect is mediated via the activation of peroxisome proliferator activated receptor alpha 
(PPAR-α) (Staels et al., 1998). PPAR-α is a ligand-activated transcription factor. The role of 
PPAR-α is to regulate the expression of genes involved in β-oxidation of fatty acids (van 
Raalte et al., 2005). Through the activation of PPAR-α, fenofibrate increases lipolysis and 
eliminates triglycerides from plasma by activating lipoprotein lipase (Staels et al., 1998). 
Fibrates stimulate the uptake of FFAs by hepatic cells and the conversion of FFAs to acyl-
CoA derivatives by the ß-oxidation
 
pathways in mitochondria resulting in a reduction in fatty 
acid and
 
triglyceride synthesis (Staels et al., 1998). 
Pharmaceutical industries are still emerging worldwide to develop more effective 
pharmacological agents, however, the efficacy of these agents has been debatable due to their 
unwanted side effects and because they can be quite costly and inaccessible to low resourced 
communities. Hence, the importance of medicinal plants has not been diminished. Natural 
products are  known to play a significant role in the development of modern medicine (Joseph 
and Raj, 2010). Hence, the World Health organization estimates that more than 70 percent of 
the population in underdeveloped and developing countries rely on traditional plants for 
medicinal treatment and primary health care (WHO, 2008)                      
 Aloe vera is one of the few medicinal plants that has stood the test of time as a popular herbal 
medicine with wide spread use in many cultures around the world (Tanaka et al., 2006). 
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1.1.4. Aloe vera 
 
The plant Aloe vera is widely distributed in Africa with origins in the Arabian Peninsula of 
Northern Africa.  Aloe vera is a member of the Liliaceae family; the family includes 300 or 
more species (Rajasekaran et al., 2006).  Aloe vera commonly called Aloe is a cactus like 
short-stemmed succulent plant with green sharp pointed leaves that are fleshy and spiny 
containing a clear viscous gel (Joseph and Raj, 2010). Aloe vera grows in arid climates and 
can reach heights of 10-20 meters with a stem ranging up to three meters in diameter. The 
flowers are produced annually in summer, they are bright orange in colour and spike up to 90 
cm tall (Yates, 2002). The term Aloe is derived from Arabic “alloeh” which means a bitter 
substance (Joseph and Raj, 2010). The bitterness results from the presence aloin and aloe-
emodin (Joseph and Raj, 2010). Aloe vera secretes two types of fluid containing proteins and 
cellular elements. One is a reddish-yellow thick bitter fluid secreted from the pericyclic cells 
of the plant and the other, a transparent mucilage gel produced by tubular cells in the central 
parenchyma zone of the leaf (Joseph and Raj, 2011). These fluids are mainly used for laxative 
(reddish-yellow) and several medical (gel) purposes some of which will be summarized in the 
following sub sections. 
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1.1.4.1. Classification 
 
Kingdom  : Plantae 
Division   : Magnolio 
Class        : Liliopsida 
Order       : Liliales 
Family     : Aloaceae  
Genus      : Aloe 
Species    : vera 
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                                                   Figure 1.2. Aloe  vera plant 
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Figure1.3. Aloe vera plant and the bioactive chemical constituents 
(http://mumbai.olx.in/Aloe-vera-products-id-4852352) 
 
1.1.4.2. Structural composition and bioactive chemical 
constituents 
 
Structural composition  
The Aloe leaf is divided into two parts, an outer green rind and the inner colourless 
parenchyma containing gel (Hamman, 2008). The Aloe vera gel contains up to 99.5 % water 
with an average pH of 4.5, the remaining 0.5-1 %  is solid material (Eshun and He, 2004; 
Hamman, 2008). Various chemical constituents have been isolated from both the solid and the 
gel material of the Aloe vera leaf (Figure 1.3). The solid material consists of many bioactive 
compounds. The many health benefits of Aloe vera have been attributed to its bioactive 
constituents found in the gel of the leaves (Hamman, 2008). Present in the gel are 
13 
 
polysaccharides such as proteins, glucomannan, calcium, zinc, glucose, salicylic acid, 
vitamins, lignins, saponins and amino acids (Atherton, 1998). Chemical compounds such as 
anthraquinones (alion, aloe-emodin) are found in the latex leaf lining (Kemper and Chiou, 
1999). Components present in Aloe vera are summarized in the table (Table 1.1) and described 
in more detail below. 
Table 1.1: Bioactive chemical constituents of Aloe vera (Hamman, 2008; Josephs and 
Raj, 2010). 
Class Compounds 
Vitamins B1, B2, B6, choline, β-carotene, folic acid 
Proteins Lectins, lectin-like substances 
Polysacccharides Mannan, acetylated mannan, glucomannan, galactan, cellulose, 
pectic substance 
Anthraquinones Aloe-emodin, aloetic-acid, Aloin A and B, emodin, chromones 
Enzymes Alkaline phosphate, amylase, carboxypeptidase, catalase, lipase 
Monosaccharides Mannose, aldopentose, glucose, L-rhamnose 
  
Amylase and lipase are biochemical catalysts that play an important role in digestion by 
breaking down fats and sugars (Fermenia et al., 1999). The presence of carboxy-peptidase 
plays an important role in the reduction of inflammation. Following tissue injury, bradykinin 
produces pain associated with vasodilation during inflammation. When Aloe vera is used to 
treat inflammation, it hydrolyses bradykinin by carboxy-peptidase and helps reduce 
inflammation by producing an analgesic effect (Obata et al., 1993; Shelton 1991). 
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Aloe vera also contains significant quantities of minerals such as sodium, potassium, calcium, 
magnesium, manganese, copper, zinc, chromium and iron. These minerals play an important 
role in the functioning of various enzymes. For example, magnesium helps inhibit histidine 
decarboxylase preventing the formation of histamine from the amino acid histidine (Shelton 
1991). Histamine is involved in allergic reactions causing itching and pain (Shelton 1991). 
Sugars contained in Aloe vera are found in the mucilage layer of the plant under the rind, 
surrounding the gel (Joseph and Raj, 2010). They mainly comprise both mono- and 
polysaccharides such as acemannan, however the most common are the polysaccharides 
specifically the gluco-mannans (Beta - (1, 4) - linked acetylated mannan). When taken orally, 
some of these bind to receptor sites that line the gut and form a barrier, possibly helping to 
prevent ‘leaky gut syndrome’ i.e. preventing absorption of unwanted material. Some can also 
be ingested by enterocytes, through a process of cellular absorption known as pinocytosis. 
Unlike other sugars that are broken down prior to absorption, the polysaccharides can be 
absorbed in the same form without being broken down. Once in the bloodstream, they act as 
immuno-modulators where they play a role in enhancing and retarding the immune response 
(Green, 1996; Kahlon et al 1991). 
Aloe vera consists of free anthraquinones and their derivatives such as barbaloin, isobarbaloin, 
anthrone-C-glycosides and chromones found in the sap. These compounds play an important 
role in absorption from the gut. Anthraquinones also exert antimicrobial properties and 
analgesic effects (Joseph and Raj, 2010).  
 
15 
 
1.1.4.3. Therapeutic uses of Aloe vera 
 
Aloe vera is one of the most significant plants used in modern traditional medicine and has 
gained its popularity in homeopathy and conventional medicine over the centuries (Joseph and 
Raj, 2010). Aloe vera has been shown to have therapeutic effects for several conditions and 
ailments such as cancer, cardiovascular disorders, wounds, inflammation and metabolic 
dysfunction (e.g. diabetes mellitus).  
Immunomodulatory and antitumor effects  
Fresh leaves and exudates i.e. lectin-like substances extracted from Aloe plants may have 
biological activities that may boost the immune system and alternatively destroy cancerous 
tumors (Winters, 1993).  Polysaccharides from the central gel of Aloe vera such acemannan 
have beneficial anti-cancer effects. Its therapeutic effects are through the activation of immune 
cells such as macrophages thus destroying tumor cells (Zhang and Tirzard, 1996).  
 
 
 
Wound healing 
 
One of the fundamental uses of Aloe vera is an aid in wound healing. Several studies have 
shown that Aloe vera is effective on wound healing (Feily and Namazi, 2009). Evidence on 
the effects on wound healing is however limited and contradictory (Vogler and Ernest, 1999). 
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Some studies have shown Aloe vera to promote wound healing while others observed that 
wounds to which Aloe vera was applied were slower to heal (Schmidt and Greenspoon, 1991; 
Kaufman et al., 1988). A meta-analysis intervention study that included clinical trials for burn 
healing provided some evidence to support that topical application of Aloe vera could be 
effective in burn wound healing for first to second degree burns (Maenthaisong et al., 2007).  
 
Anti-inflammatory and antibacterial effects  
 
Aloe vera is reported to have anti-inflammatory effects when used topically (Reuter et al., 
2008). The plant has also been shown to reduce the inflammatory response in rats with 
carrageenan-induced arthritis (Davis et al., 1992), an animal model which mimicks 
rheumatoid arthritis in humans. The anti-inflammatory therapeutic effects of Aloe vera are 
thought to be through the stimulation of fibroblast cell growth and the inhibition of 
arachidonic acid pathways via cyclooxygenase (Vazquez et al., 1996). The inhibition of the 
biosynthetic pathways of prostaglandins is through active steroid-like compounds contained in 
the central part of the leaf (Reuter et al., 2008). Aloe vera has also been shown to have 
antibacterial activities that are thought to play a role in the treatment of minor skin infections 
and may possibly inhibit fungal growth (Sumbul et al., 2004). 
 
Antidiabetic effects  
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Evidence show that Aloe vera may play a role in the treatment of diabetes mellitus. Previous 
studies have shown that oral administration of processed Aloe vera gel reduced circulating 
blood glucose levels in an obese mice model (Kim et al., 2009). Aloe vera has been shown to 
lower blood glucose, cholesterol and lipid levels in streptozotocin-induced diabetes rat models 
and its administration significantly increased plasma insulin levels (Hamman, 2008). Similar 
findings were also reported where Aloe vera leaf pulp lowered blood glucose levels in 
neonatal STZ-induced type- II diabetic rats (Can et al., 2004). The antidiabetic effects of Aloe 
vera are thought to be due to the presence of mannans antraquinones and lectins (Can et al., 
2004). It has also been suggested that the mechanism by which Aloe vera lowered the blood 
glucose levels was by enhancing glucose metabolism (Hamman. 2008). 
Most medicinal plants are taken orally and as a consequence the first point of contact with the 
body is the gastrointestinal tract (GIT). The next section gives a brief overview on the GIT. 
1.1.5. Gastrointestinal system 
The gastrointestinal tract (GIT) is a complex organ serving as the first point of entry of any 
orally administered dietary ingesta (Sorensen, 2009). Hence, the structure of the GIT is well 
adapted to carry out several functions that include digestion, absorption and protection.  
For most mammalian species, the development of the GIT is divided into three stages: (i) the 
prenatal stage characterized by minimal stimulation from the GIT lumen. (ii) The neonatal 
stage, at this stage the development of the GIT is stimulated by liquid feed from the mother’s 
milk and (iii) the post-weaning stage, which  is a stage that involves the adaptation of the GIT 
to utilize solid feeds (Zabielski et al., 2008).  At the beginning of weaning, the motility, 
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digestive and absorptive functions of the GIT are yet to be developed and prepared for solid 
feeds, hence this is the most critical stage for the structure of the GIT to develop to its full 
capacity.   
Although the GIT mucosa undergoes structural and functional changes in structures such as 
the villi and crypts which are related to exchange and absorptive processes during postnatal 
development (Vigueras et al.,1999), diet plays a major role  in the structure and the 
functioning of the GIT by inducing the release of regulatory and tropic hormones  (Sorensen, 
2009). 
Aloe vera contains bioactive compounds such as carbohydrates and proteins (Hamman, 2008; 
Josephs and Raj, 2010). Carbohyrates can influence the GIT’s response to a diet and result in 
adaptive changes in the GIT (Lairon et al., 2007). Some compounds found in complex 
carbohydrates are not digested until they reach the large intestine, hence their physical and 
chemical properties may have an important physiological effect throughout the GIT 
(Schneeman, 2007). Carbohydrates such as non-starch polysaccharides have properties such as 
water-holding capacity and non-digestibility, as a result these compounds are primary 
substrates for growth of micro flora in the large intestine where they function as prebiotics 
(Schneeman, 2007). 
A study done in human subjects showed that Aloe vera supplementation decreased the stool 
specific gravity; this indicated a water-holding property and improved gastrointestinal motility 
(Bland, 1985). Bland (1985) also found Aloe vera to have alkalizing effects where the 
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gastrointestinal pH increased after Aloe vera administration. Aloe vera also improved protein 
digestion and absorption (Bland, 1985).  
The GIT is sensitive to dietary manipulation during the neonatal stage. Therefore, the 
ingestion of Aloe vera in growing rats might have a direct long lasting effect on the GIT 
structure and function (Pacha, 2000). Medicinal plants can be toxic especially when used 
chronically, it is therefore important to also asses their effects on the general health status of 
individuals using them by monitoring specific surrogate markers of organ function. 
 
1.1.6. Justification of the study 
 
Previous studies exploring the metabolic effects of Aloe vera have been in adult animals and 
the metabolic dysfunction has generally been induced by use of pharmacological agents such 
streptozotocin (STZ). Several rat models have been used for in vivo studies on obesity and 
diabetes mellitus. These include the use of pharmacological agents such as streptozotocin and 
genetic strains such as obese Zucker rats (Buettner et al., 2006). However, these models do not 
represent childhood metabolic dysfunction sufficiently. The current study on recently weaned 
rats exposed to a high-carbohydrate diet was an attempt to fill part of the lack of information 
on the effects of Aloe vera on diet-induced metabolic dysfunction in growing rats as an 
experimental model for the condition in children. 
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1.1.7. Aims of the study  
 
The aim of the study was to evaluate whether Aloe vera delays the development of a high 
carbohydrate diet-induced metabolic dysfunction in growing rats. Thus, the major objectives 
were to: 
a)  Establish an animal based  model of diet-induced metabolic dysfunction  
b) Explore whether dietary supplementation with Aloe vera delayed the development of 
diet-induced metabolic dysfunction in growing rats by exploring its regulatory 
mechanism with special focus on its effect on concentrations of: 
        i) Circulating insulin and metabolic substrates (glucose, triglycerides and free fatty acids)  
       ii) Hepatic storage of metabolic substrates (lipids and glycogen) 
c) Determine the effects of Aloe vera on the morphometry and morphology of the 
abdominal viscera by gross macroscopic and microscopic measurements.  
d) Determine the effects of Aloe vera on growth performance (body mass and linear 
growth).  
e) Assess the effects of Aloe vera extracts on surrogate markers of liver function i.e. 
alkaline phosphatase (ALP), alanine transaminase (ALT), gamma glutamyl 
transpeptidase (GGT) and total bilurubin (TBIL). 
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I thus hypothesized that: 
a. The high carbohydrate diet would induce metabolic dysfunction in the rats after 
20 weeks of feeding and 
b. Administration of Aloe vera would prevent/delay the development of the diet 
induced metabolic dysfunction without adverse effects in the rats. 
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CHAPTER TWO-MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
 
23 
 
2.1. Study setting 
The study was conducted in the Central Animal Services animal unit and the School of 
Physiology at the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 
South Africa. 
2.1.1. Ethical approval 
 
Ethical approval for the study was obtained from the Animal Ethics Screening Committee 
(AESC) of the University of the Witwatersrand (Ethics clearance number: 2010/45/2A) and 
the study was undertaken according to international standards of animal care and use in 
research. To comply with restrictions by the AESC in vivo acute toxicity studies were not 
performed in this study. 
 
2.1.2. Experimental design 
 
Fifty-nine male, 21 day old Sprague Dawley rats were randomly divided into six treatment 
groups. Group I received normal rat chow + plain gelatine cubes (NRC) and served as the 
control. Group II received a high carbohydrate diet + plain gelatine cubes (HCD) and group III 
received normal rat chow + fenofibrate (100 mg.kg
-1
)
  
(NRC + FENO). Group IV received a 
high carbohydrate diet + fenofibrate (HCD + FENO) and group V received normal rat chow + 
Aloe vera (300 mg.kg
-1
) (NRC + Av).The last group (group VI) received a high carbohydrate 
diet + Aloe vera (HCD + Av). The Aloe vera and fenofibrate were administered daily in 2 ml 
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gelatine cubes, which were prepared as described by Kamerman et al., (2004). The fenofibrate 
was used as a positive control pharmacological agent. 
 
 
2.2. Materials 
 
2.2.1.  Plant collection 
 
Fresh Aloe vera plants were sourced from a commercial plant nursery (Flora farm) in 
Boksburg, South Africa. The farm is on longitude of 28 
0 24’15 East and latitude 26 0 82’10 
South with a mean annual minimum temperature of 14 
0
C, mean annual maximum 
temperature of 30 
0
C, mean annual minimum rainfall of 450mm and mean annual maximum 
rainfall of 500mm. The Aloe vera plant was authenticated by the University of the 
Witwatersrand Herbarium Research and Media Officer, Mr Donald McCallum. A sample of 
the plant was deposited in the University Herbarium with voucher number: Ben Beya 1. 
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2.3. Methods 
 
2.3.1. Preparation of Aloe vera leaf extracts  
 
The crude Aloe vera leaf extract was prepared from fresh Aloe vera leaves as modified from  
Rajasekaran et al., (2004) so as to include some solid particulate leaf matter. The Aloe vera 
leaves were washed with distilled water, sliced and homogenized with an equal volume of 
distilled water using a blender (Warring ®, Lasec SA Company, USA). The homogenate was 
filtered through a muslin cloth. The filtrate was dried in an oven (Salvis ®, Oakton 
Instruments, USA) at 40 
0
C and the resultant residue was stored in tightly dark, tightly sealed 
bottles at 4 
0
C and then the requisite amounts of Aloe vera extracts were suspended in gelatine 
cubes at the time of administration to the animals. To prepare the gelatine cubes, 8g gelatine 
(Davis gelatine, Johannesburg, South Africa), 17 g brown sugar (Tongaat Hulett South Africa 
Ltd) and 5mL Bovril (Bovril, Uniliver, Johannesburg, South Africa) were mixed in 100 mL of 
boiling water (Kamerman et al., 2004). 
 
 
2.3.2. Feeds 
 
The experimental diet was high in carbohydrates and fats, and resembled a Western diet 
(Pickavance et al., 1999). To prepare the high carbohydrate diet, 1.32 kg of normal rat chow 
powder, 280 g brown sugar (Tongaat Hulett South Africa Ltd), four cans (385 g) of condensed 
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milk (Nestle gold cross full cream sweetened condensed milk, Nestle South Africa) was mixed 
in 800 ml of boiling water. The high carbohydrate diet (experimental diet) consisted of 65 % 
carbohydrates derived from maize and simple carbohydrates (sugar), 19 % protein derived 
from soya and fish, 16% fat derived from milk products and fish (Majane et al., 2009; du Toit 
et al., 2008). The diet has previously been shown to induce hyperphagia (Pickavance et al., 
1999). To prepare the control diet, normal rat chow (Epol, South Africa) was mixed in  water 
to make a similar pasty consistency to the high carbohydrate diet. In comparison, the control 
diet consisted of 60 % carbohydrates derived from maize, 30 % protein derived from soya and 
fish and 10 % fat derived from fish without milk products. 
2.3.3. Housing of animals 
The animals were housed individually in standard rat cages with bedding of hard wood shavings, 
pieces of paper were added to the cages for environmental enrichment. The rats were kept in a 
controlled environment with a room temperature of 22 ± 1 
0
C and 12 h light-dark cycle (lights on 
07:00 to 19:00). The rats were allowed to adapt to the housing conditions and interventions (feeding 
and weighing) three days before the commencement of the experimental trials. The animals were 
given access to food and water ad libitum.   
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2.4.Analytical procedures 
2.4.1. Body mass 
 
The rats were weighed (Precisa balance 310M, Instrulab, Switzerland) twice a week to 
monitor growth performance. The body mass measurements also allowed for adjustment of the 
amount of Aloe vera and fenofibrate (SIGMA, USA) in the gelatine cubes to maintain a 
constant dosage rate over the 20-week study period. 
 
2.4.2. Oral glucose tolerance test and measurement of fasting metabolic 
substrates (triglycerides and glucose) 
 
After the 20
th
 week of intervention, the rats were fasted overnight, restrained in perspex rat 
restrainers for one hour and then blood was collected following a pin-prick of the tail with a 
sterile 21G needle  (Loxham et al., 2007). The collected blood was used to determine fasting 
glucose and triglycerides using a calibrated glucometer (Glucometer Elite ® 3947, Bayer 
Company, Japan) and a calibrated triglyceride meter (Accutrend triglycerides, Roche 
Company, Mannheim, Germany) respectively. Immediately after the fasting metabolic 
substrate measurements, an OGTT was performed to assess the rats’ ability to tolerate a 
glucose load. The fasted rats were orally gavaged with glucose (3g.kg
-1
) made up at 50% w/v 
solution, D-Glucose, Sigma Aldrich) and blood was collected from the tail tip at 15, 30, 60, 
120 and 180 min after glucose administration (Loxman et al., 2007: Muellenbach, 2009). The 
blood glucose concentrations were determined using a glucometer as described earlier. 
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2.5.Terminal Procedures 
 
Following the OGTT the rats were put back on to their respective diets for 48 hours and then 
fasted for 12 hours before being euthanased by  overdose of sodium pentobarbitone (Eutha-
naze, Centaur labs, Johannesburg, South Africa) administered intra-peritonially at 150 mg.kg
-1 
body mass.  
 
2.5.1. Blood sampling and plasma processing 
 
After the animals were euthanased, blood samples were collected via cardiac puncture using 
21G needles and 10ml syringes. Half of the blood (5 mL) was transferred into plain blood 
tubes (Geiner Bio-one GmbH, Austria) and the rest into EDTA tubes (Novo Nordisk 
Company, Johannesburg, South Africa). The blood samples were spun for 10 min at 5000 x g 
at 10 
0
C in a centrifuge (SorvallRT ®6000B, Pegasus Scientific Inc., Rockville USA). The 
plasma and serum were collected and then stored at -20 
0
C for the analysis of free fatty acids, 
insulin and markers of liver function. 
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2.5.2. Visceral measurements and histology 
 
After euthanasia, the thorax and abdomen were cut open by midline incision and the viscera 
namely the visceral fat (abdominal fat pad), liver, pancreas, stomach, caecum, large and small 
intestines were harvested and weighed (Precisa balance 310M, Instrulab, Switzerland). The 
intestines were gently stretched out on a board and their lengths were measured using a ruler. 
The stomach and the intestines were then emptied of their content and weighed. The mass of 
the liver was also recorded and part of the liver was stored at -20
0 
C for determination of lipid 
and glycogen content. Segments (1cm long) of the small intestine and the liver were collected 
for histology and stored in 10 % formalin in phosphate buffered saline. The intestinal 
segments and liver samples were routinely processed and stained using haematoxylin and 
eosin. The slides were viewed under a light microscope using an eye piece micrometer 
(Reichert®, Austria). For the small intestines the villus heights and crypt depths were 
measured. An assessment of morphometry of the liver was done under the light microscope to 
assess for signs of pathology. Using a high power magnification of 400X, the liver cell size 
and the number of cells within a linear field 100 μm was measured.  
 
2.5.3. Determination of liver lipid content 
 
The procedure by Bligh and Dyer (1959) was followed for the extraction of lipids. Briefly, the 
frozen liver samples were thawed and 5-7 g of the frozen liver sample was steeped in 50 ml of 
chloroform methanol (2:1) (MERCK Chemicals, South Africa). The samples were then 
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incubated overnight at 4
0
C. The samples were filtered through a filter paper (Whatmann®, No 
1 size 50 mm, England) into a separating funnel and 30 ml 0.9 % of saline was added and 
mixed thoroughly. The solution was then left overnight to separate into two layers. The bottom 
layer (chloroform) was collected into a round bottomed flask (SCOTT DURAN, Germany) 
and the lipids were recovered by evaporating the solvent at 37
0 
C using a rotor evaporator 
(Labocon (Pty) Ltd, Krugersdrop, Transvaal, South Africa). The residual oil was then made up 
to 20ml with chloroform and stored at 4 
0
C. To determine the percentage of lipids in each 
sample, an aliquot of 2 ml was collected into a dry pre-weighed vial and re-dried at 50 
0
C, in 
an oven (Salvis ®, Oakton Instruments, USA). The mass of the lipid, multiplied by a factor of 
10, was expressed as a percentage of the original weight of the liver sample.  
 
2.5.4. Determination of hepatic glycogen content  
 
Liver glycogen was determined by a method of indirect hydrolysis as described by Passonneau 
and Lauderdale (1974). In summary, 0.1 g liver sample was homogenized  in 1ml of 0.03M 
HCl using an ultra turrex homogenizer (Janke & Kunkel GmbH & Co IKA-Werk D7813, 
Staufen). One milliliter of 1M HCl was then added to hydrolyse the glycogen, the tubes were 
sealed and allowed to stand in boiling water for 2 hours. A volume of 1mL 1M NaOH was 
then added to neutralise the acid before the determination of glucose. The glucose 
concentration was determined using a glucose-oxidase based reaction on Accu-Chek Active 
glucose meter (Roche, Germany). Glycogen concentration was reported as glucose equivalents 
in the homogenate. 
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2.5.5. Tibia lengths and masses  
 
The right femoral head was dissected away from the acetabulum at the hip joint and the soft 
tissues were removed from the bones (tibia). The length of the tibia was  measured using a 
ruler. The bones were then dried in an oven (Salvis ®, Oakton Instruments, USA) at 40 
0
C for 
7 days (until constant mass) and then weighed to determine their dry mass. 
The density of the bones was calculated using the following formula:  
  Bone density (mg.mm
-1
) = Mass of the bone (mg) / length of the bone (mm) 
 
 
2.5.6. Plasma free fatty acid concentrations 
 
The concentration of free fatty acids in plasma was determined colorimetrically using a free 
fatty acids half-micro test kit (Roche Diagnostic, Germany) according to the manufacturer’s 
instructions. All the reagents were supplied in the kit; however, additional reagents for the 
preparation of a palmitic acid standard solution were required and were supplied by SIGMA 
Aldrich (South Africa). The standard solution was prepared according to the manufacturer’s 
instructions. The assay employed an optimized enzymatic colorimetric technique for free fatty 
acids. Standards, controls and samples were pipetted into 96 well polystyrene microplates.  
Absorbances were read using a spectrophotometer (Labsystems, Multiskan, Ascent, AEC 
Amersham) which measured the intensity of colour at a wavelength of 546 nm.  According to 
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the manufacturer’s instructions, the kit had a dilution limit of 1.5 mM free fatty acids. The 
concentrations of free fatty acids in each sample was then calculated using the formula:   
C= (V/ε x d x v) x Δ A (mM sample solution), where: 
C= Concentration (mM) 
V= Final volume (ml) 
v= Sample volume (ml) 
d= light path (cm) 
ε= absorption coefficient of dye at 546nm 
Δ A= Absorbance difference 
 
2.5.7. Measurement of liver enzymes and total bilirubin in serum 
 
The alkaline phosphatase (ALP) enzyme activity (U.L
-1
) was measured using a Reflotron 
machine (Reflotron ®, Roche diagnostics LTD, Burgess Hill West Sussex, RH159RY, United 
Kingdom). The machine was calibrated according to manufacturer’s instructions, after which 
drops of serum were placed on the test strips. The test strips for the alkaline phosphatase were 
Reflotron ® (ALP) (Roche Diagnostics GmbH, Mannheim, Germany). The serum 
concentrations of total bilirubin (TBIL), gamma-glutamyl transferase (GGT) and alanine 
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transaminase (ALT) were measured using a calibrated colorimetric chemistry analyser 
(IDEXX VetTest ® Chemistry Analyser, The Netherlands).  
 
2.5.8. Insulin measurements 
 
The hormone insulin was determined by enzyme linked immunosorbent assay (ELISA) using 
a Rat insulin kit (DRG ®, Rat Insulin High Range, USA) according to manufacturer’s 
instructions. The manufacturers indicate that the kit is 100% specific and has been validated 
for the determination of rat insulin. All reagents and plates were supplied in the kit. The assay 
employed a quantitative sandwich enzyme immunoassay technique which utilizes a 
monoclonal antibody specific for rat insulin. Absorbencies were measured at 450 nm using a 
plate reader (Multiskan Ascent, Lab system, model nº 354, Helsinki, Finland). A standard 
curve was constructed and the concentrations of insulin in the samples were determined. The 
kit had a detection limit of 1.5μg.L-1.  
 The fasting glucose levels and insulin data were then used to determine fasting whole-body insulin 
sensitivity using the homeostasis model assessment of insulin resistance (HOMA-IR) by using the 
formula described by Mathews et al., 1985:  
[Fasting plasma glucose (mg.dl
-1
) × fasting plasma insulin (µU.mL
-1
)] / 405  
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2.5.9. Statistical analysis 
 
All data are expressed as mean ± standard error of mean (SEM). A one way analysis of variance 
(ANOVA), followed by a Bonferroni post hoc test, was used to detect differences between the 
groups to assess the effect of Aloe vera on the parameters measured.  A repeated measures ANOVA 
was used for statistical analyses of the OGTT. Statistical significance was accepted at p<0.05. All 
the statistical analysis was performed using Graph Pad Prism version 5.0 (Graph Pad software, San 
Diego, C.A). 
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            CHAPTER THREE-RESULTS 
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      3.1. Mortality and morbidity of the animals 
During the study, all the animals remained healthy and consequently no incidental or 
iatrogenic rat mortalities were recorded. 
3.2. The effects of Aloe vera leaf extract on body mass gain 
Figure 3.1 shows the initial and terminal body masses of the rats. There was no significant 
difference observed (p>0.05) in the initial body mass between the rats in the different groups. 
After 20 weeks on the various treatments, all animals had a significant increase in body mass 
gain (p<0.0001). The rats fed a HCD had significantly (p<0.001) higher body masses as 
compared to the other groups, however fenofibrate administration prevented the HCD-induced 
increase in body mass whilst Aloe vera administration had no significant effect. 
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Figure 3.1. Effect of Aloe vera leaf extract on body mass gain 
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 mg.kg
-1
); 
Av, Aloe vera (300 mg.kg
-1
). The data in figure 3.1 show that there were no differences 
(p>0.05) in the initial body mass of rats (n=59) allocated to the different groups at 3 weeks of 
age (initial mass), however all rats had a significant increase in body mass after 20 weeks 
(final mass) of intervention. Rats fed a HCD had a significantly increased body mass 
compared to others after 20 weeks of intervention; however, fenofibrate administration 
prevented the diet-induced increase in body mass whilst Aloe vera had no significant effect. 
Data is represented as mean ± SEM. **: p<0.001; ***: p<0.0001. 
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          3.3. The effect of Aloe vera leaf extract on the linear growth (tibia)  
There were no significant differences observed in the lengths of the tibia (Table 3.1) between 
the groups (p>0.05). There were also no significant differences in the tibia masses and 
densities of the bones. 
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Table 3.1 Effect of Aloe vera leaf extract on the length and mass of the tibias of growing rats.  
 
 
 
 
 
 
 
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate;  Av, Aloe vera. The results in this table show   that 
there were no significant (p>0.05) differences between the groups. Data is represented as mean ± SEM.  n= 10 per group except for 
NRC + FENO where n= 9. 
 NRC 
n=10 
HCD 
n=10 
NRC + FENO 
n=9 
HCD + FENO 
n=10 
NRC + Av 
n=10 
HCD + Av 
n=10 
Tibia 
 
      
Length (mm) 
 
44.70±0.45 44.20±0.51 44.00±0.97 42.40±0.82 44.60±0.64 43.00±0.67 
Mass (mg) 
 
0.86±0.04 0.78±0.04 0.88±0.06 0.78±0.10 0.90±0.07 0.91±0.04 
Density (mg.mm
-1
) 
 
0.02±0.00 0.02±0.00 0.02±0.00 0.02±0.00 0.02±0.00 0.02±0.00 
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          3.4. The effect of Aloe vera leaf extract on circulating insulin and metabolic         
 substrates 
Table 3.2 shows the circulating levels of metabolic substrates and insulin of the growing rats 
after the 20-week intervention.  There was no significant difference (p>0.05) in the plasma 
concentrations of free fatty acids, insulin, HOMA-IR, fasting glucose and triglycerides 
between the groups.   
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Table 3.2: Effect of Aloe vera leaf extract on fasting concentrations of metabolic substrates and circulating insulin.    
 
 
 
 
 
 
 
 
Key: FFAs, free fatty acids; TGs, triglycerides; NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate; Av, Aloe 
vera; HOMA-IR, homeostasis model assessment of insulin resistance (HOMA-IR)  . The results in this table indicate that there 
were no differences in circulating metabolic substrates, insulin and the HOMA-IR in all the groups (p>0.05). Data is presented as 
mean ± SEM.   n= 10 per group except for NRC + FENO where n= 9. 
 NRC 
n=10 
HCD 
n= 10 
NRC+FENO 
n= 9 
HCD + FENO 
n= 10 
NRC + Av 
n= 10 
HCD + Av 
n= 10 
 
Glucose (mmol.L
-1
) 
  
 
 
3.61±0.16 
 
 
3.74±0.12 
 
 
3.87±0.16 
 
 
3.77±0.15 
 
 
3.64±0.15 
 
 
3.69±0.16 
 
FFAs (mM) 
 
0.21±0.04 
 
0.20±0.02 
 
0.15±0.01 
 
0.19±0.04 
 
0.19±0.01 
 
0.16±0.01 
 
TGs  
(mmol.L
-1
) 
 
 
1.54±0.09 
 
1.96±0.13 
 
1.45±0.23 
 
1.77±0.20 
 
1.26±0.02 
 
1.42±0.11 
 
Insulin 
(μg.L-1) 
 
124.60±11.71 
 
141.37±16.94 
 
139.95±16.03 
 
135.17±18.81 
 
159.68±11.69 
 
123.38±14.80 
 
HOMA-IR 
 
20.05±2.13 
 
23.40±3.08 
 
24.05±2.88 
 
22.23±2.87 
 
25.71±1.83 
 
20.32±2.62 
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           3.5. Effects of Aloe vera leaf extract on abdominal visceral organ morphometry 
 and morphology 
Due to observed differences in body mass of the rats after the interventions, when considering 
the relative mass/length of the visceral organs, I also expressed them relative to tibia length, 
which was not significantly different between the groups. Figure 3.2 shows the relative mass 
of the visceral fat of the growing rats after the interventions. Feeding rats a HCD significantly 
(p=0.003)) increased the visceral fat mass. Fenofibrate administration prevented the HCD-
induced visceral fat mass gain whilst Aloe vera administration had no effect. Figure 3.3 shows 
the relative mass of the liver of the growing rats after the interventions. There was a 
significant increase in the relative mass of the liver of growing rats administered fenofibrate. 
Table 3.3 shows that there was no significant difference in the absolute mass of the large 
intestine, however, when considering the large intestine mass relative to tibia length, rats fed a 
HCD alone had significantly lower large intestine mass than others. There was no significant 
difference in the absolute stomach mass across the groups, however when considering the 
relative mass of the stomach, rats fed a NRC+FENO had significantly (p<0.0001) higher mass 
than others. The diets, drug intervention and Aloe vera had no significant effect on the small 
intestinal villus height and crypt depth (p>0.05) (Table 3.4). There were no signs of 
histopathology in the microscopic examination of the liver (data not shown). There were no 
significant differences in the cell size (NRC= 6.10 ± 0.23 μm) vs (FENO= 6.56 ± 0.24 μm) of 
the hepatocytes and the number of cells per 100 μm length of a high power field (NRC= 10.32 
± 0.19 μm) vs (FENO= 10.39 ± 0.18 μm).  
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Figure 3.2. Effect of Aloe vera leaf extract on visceral fat mass 
 Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 mg.kg
-1
); 
Av, Aloe vera (300 mg.kg
-1
); TL, tibia length. The data in  Figure 3.2 shows that after 20 
weeks of intervention the relative mass of the visceral fat (expressed as a percentage tibia 
length) of the rats fed a HCD was significantly greater than the rats in the other groups, 
however fenofibrate administration prevented the diet-induced increase in visceral fat mass 
whilst Aloe vera had no effect. The data is presented as mean ± SEM. **: p<0.003. n= 10 per 
group except NRC + FENO where n=9. 
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Figure 3.3. Effect of Aloe vera leaf extract on the liver mass 
 Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 mg.kg
-1
); 
Av, Aloe vera (300 mg.kg
-1
); TL, tibia length. The data in Figure 3.3 shows that after 20 weeks 
of intervention the mass of the liver (expressed as a percentage tibia length) of the rats 
administered with fenofibrate was significantly greater than that of rats in the other groups 
whilst Aloe vera had no significant effect. Data is presented as mean ± SEM. *: p<0.05; ***: 
p< 0.0001. n= 10 per group except NRC + FENO where n= 9. 
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Table 3.3: Effect of Aloe vera leaf extract on the absolute mass and the mass (% relative to tibia length) of the viscera and, 
length of GIT segments of growing rats.  
Organs NRC 
n=10 
HCD 
n=10 
NRC + FENO 
n=9 
HCD + FENO 
n=10 
NRC + Av 
n=10 
HCD + Av  
n=10 
                    
      
Visceral fat (g) 
 
15.90 ± 1.31 26.42 ± 1.56** 16.64 ± 3.40  17.74 ± 1.52 15.55 ± 0.99 25.11 ± 2.26** 
Liver (g) 
 
13.69 ± 0.38 15.92 ± 1.17 17.92 ± 0.85* 18.84 ± 1.26* 14.10 ± 0.57 14.33 ± 0.49 
LI (g) 2.47 ± 0.09 
 
2.05 ± 0.10 
 
2.20 ± 0.06 
 
2.03 ± 0.07 
 
2.33 ± 0.08 
 
1.99 ± 0.09 
 
LI (g) (%TL) 5.51 ± 0.15 
 
4.62 ± 0.20* 
 
5.04 ± 0.24 
 
4.81±0.21 
 
5.24±0.17 5.24±0.17 
LI (mm) 248.50 ± 6.91 223.00 ± 9.07 252.22 ± 8.94 230.00 ± 9.19 253.00 ± 9.43 241.00 ± 6.23 
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Table 3.3 cont. 
SI (g) 
 
 
8.72 ± 2.77 
 
 
9.32 ± 2.94 
 
 
9.38 ± 3.14** 
 
 
8.94 ± 2.77 
 
 
9.25 ± 2.96 
 
 
9.00 ± 2.85 
 
SI (g) (%TL) 
 
19.46 ± 1.35 
 
21.09 ± 0.70 
 
21.46 ± 0.88 
 
21.22 ± 0.98 
 
20.72 ± 0.58 
 
20.96 ± 0.74 
 
SI (mm) 
 
1395.00 ± 19.69 
 
1288.00 ± 18.90 
 
1387.78 ± 17.78 
 
1320.50 ± 14.80 1396.00 ± 33.41 
 
1328.00 ± 31.6 
 
Stomach (g) 
 
2.26 ± 0.14 2.25 ± 0.10 2.62 ± 0.05 2.23 ± 0.07 2.40 ± 0.08 2.20 ± 0.06 
Stomach (g) (%TL) 
 
5.06 ± 0.30 5.09 ± 0.19 5.97 ± 0.19* 5.27 ± 0.17 5.38 ± 0.15 5.11 ± 0.15 
Pancreas (g) 
 
1.67 ± 0.14 1.62 ± 0.11 1.78 ± 0.13 1.65 ± 0.15 1.68 ± 0.09 1.58 ± 0.09 
 
Pancreas (g) (%TL) 3.71 ± 0.27                3.66 ± 0.23 4.24 ± 0.35 3.89 ± 0.34 3.78 ± 0.22 3.68±0.24 
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Table 3.3 cont 
Caecum (g) 
 
 
1.67 ± 0.04             
 
1.51 ± 0.071 
 
1.60 ± 0.13 
 
1.61 ± 0.11 
 
1.66 ± 0.05 
 
1.57 ± 0.08 
 
Caecum (g) (%TL) 3.75 ± 0.09 3.41 ± 0.17 3.68 ± 0.37  3. 81 ± 0.29 3.74 ± 0.14 3.66 ± 0.22 
 
 
Key: BM, body mass; SI, small intestine; LI, large intestine; g, gram.NRC, normal rat chow; HCD, high carbohydrate diet; FENO, 
fenofibrate;  Av, Aloe vera; TL, tibia length; cont, continued. Data is presented as mean ± SEM.  Data in the same row indicate 
significant differences. n= 10 per group except NRC + FENO where n=9.*: p<0.02, **: p<0.006. The results in this table indicate 
feeding rats a HCD resulted in a higher (ANOVA; p<0.003) visceral fat mass than the other groups. Fenofibrate administration 
prevented the HCD-induced visceral fat mass gain whilst Aloe vera administration had no effect. There was a significant increase 
(p<0.0001) observed in the relative mass of the liver of growing rats administered fenofibrate.  
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Table 3.4: Effect of a crude Aloe vera leaf extract on microscopic measurements of small intestine in growing rats.  
 
 NRC 
n=10 
HCD 
n=10 
NRC+FENO 
n= 9 
HCD+FENO 
n= 10 
NRC + Av 
n=10 
HCD + Av 
n= 10 
 
Villus Height 
(μm) 
 
49.20 ± 3.02 
 
53.40 ± 4.48 
 
47.75 ± 3.28 
 
58.60 ± 2.56 
 
51.20 ± 1.85 
 
48.80 ± 1.59 
 
Crypt depth 
(μm) 
 
 
22.20 ± 0.80 
 
19.80 ± 0.97 
 
21.00 ± 0.41 
 
23.00 ± 0.84 
 
20.02 ± 0.58 
 
18.80 ± 1.59 
VH/CD ratio 2.22 ± 0.10 2.70 ± 0.16 2.27 ± 0.16 2.54 ± 1.10 2.53 ± 0.08 2.59 ± 0.19 
 
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate; Av, Aloe vera.  VH, Villus height; CD, crypt depth 
(VH/CD). Results in this table indicate that the morphometry of the small intestine villi and crypts was not significantly (p>0.05) 
affected after 20 weeks of feeding Aloe vera extract.  n= 10 per group except NRC + FENO where n=9. 
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           3.5. The effect of Aloe vera leaf extract on the response to an oral glucose load 
 Figure 3.4 shows the results of the glucose tolerance test for all groups. The basal glucose 
concentrations were within the normal range i.e. 3.9 to 5.5 mmol.L
-1
. There was a significant 
increase in blood glucose levels following the glucose load with the peak blood concentrations 
attained between 30 and 60 minutes. There were no significant differences between the 
treatment groups. The blood glucose levels returned to basal levels by 180 minutes in all the 
groups. 
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Figure 3.4. Effects of Aloe vera leaf extract on the response to an oral glucose load 
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 mg.kg
-1
); 
Av, Aloe vera (300 mg.kg
-1
). The data in Figure 3.4 show the changes in blood glucose 
concentration following the oral administration of 3 g.kg
-1
 glucose solution to fasted rats. 
There was no significant difference in fasting glucose levels (time 0). There was a significant 
increase in blood glucose following glucose administration in all the groups. The peak blood 
glucose concentration which occurred between 30 and 60 minutes, were significantly higher 
than basal fasting glucose levels, and returned to basal levels by 180 minutes in all groups. 
***: p<0.0001. n=10 per group except NRC + FENO where n= 9. 
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         3.7. The effect of Aloe vera leaf extract on liver enzymes and total bilirubin 
Rats fed a NRC+ Av had significantly lower TBIL (p<0.02) as compared to rats fed a HCD. 
The ALP levels were significantly higher (p>0.01) in the FENO group, however no significant 
differences were observed in ALT levels between the groups (Table 3.5). GGT levels were 
below the detectable range (1-6 U.L
-1
) for the diagnostic equipment (VetLab) used for the 
assay in all the groups.  
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Table 3.5: Effect of Aloe vera extract on the liver enzymes (ALT, ALP and GGT) and total bilurubin of the growing rats. 
 
 NRC 
n= 10 
HCD 
n= 10 
 
NRC+FENO 
n= 9 
 
  HCD+FENO 
  n= 10 
    
       NRC + Av 
       n= 10 
        
         HCD + Av 
          n= 10 
  
 
ALP (U.L
-1
) 
 
 
ALT (U.L
-1
) 
 
 
TBIL(μmol.L1) 
 
 
 
GGT 
 
 
202.30±22.12 
 
 
20.21±1.03 
 
 
6.17±0.40 
 
 
 
nd 
 
 
 
140.30±9.07 
 
 
25.21±6.22 
 
 
9.67±1.28 
 
 
 
nd 
 
 
 
270.25±15.44** 
 
 
23.93±3.74 
 
 
7.67±1.17 
 
 
 
nd 
 
                
 
158.67±15.74 
 
 
32.76±3.84 
 
  
9.17±2.27 
 
 
 
nd 
 
                    
       
234.67±19.04 
 
 
 22.84±3.08             
 
 
3.33±1.33* 
 
            
 
nd 
 
               
           
    125.67±11.68 
 
 
   22.17±4.93 
       
 
    4.67±0.80 
 
         
 
     nd 
  
 
 
 
 
 
 
 
 
   
 
Key: NRC, normal rat chow; HCD, high carbohydrate diet;  ALP, alkaline phosphatase (normal range (36-126 U.L
-1
) ; ALT , 
alanine transaminase TBIL  , total bilurubin; LM, liver mass; FENO, fenofibrate (100 mg.kg
-1
); Av, Aloe vera (300 mg.kg
-1
); nd, not 
detectable.  The results in this table indicate that there were significantly (p<0.05) higher ALP levels in the NRC + FENO group as 
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compared to others. TBIL levels were significantly (p<0.05) lower in the NRC + Av 
group, however no differences were detected in ALT levels in all the groups (p>0.05). 
Data is represented as mean ± SEM.   n= 10 per group except NRC + FENO where n=9. 
*p<0.02; **p<0.01. 
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3.8. The effect of Aloe vera leaf extract on hepatic lipid and glycogen content  
There were no significant (p>0.05) differences observed in the hepatic lipid content 
(Figure 3.5) and in the hepatic glycogen content (Figure 3.6). 
 
55 
 
 
 
0
5
10
15
20
25
NRC
HCD
NRC+ FENO
HCD+FENO
NRC + Av
HCD+ Av
Groups
L
ip
id
 y
ie
ld
 (
%
 l
iv
e
r
 m
a
ss
)
 
Figure 3.5. Effect of Aloe vera leaf extract on hepatic lipid content of growing rats  
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 
mg.kg
-1
); Av, Aloe vera (300 mg.kg
-1
). The data in Figure 3.5 shows that there were no 
significant (p>0.05) differences observed in the hepatic lipid content of treated rats. Data 
is presented as mean ± SEM. n=10 per group except NRC + FENO where n=9.  
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 Figure 3.6. Effect of Aloe vera leaf extract on hepatic glycogen content of growing rats 
Key: NRC, normal rat chow; HCD, high carbohydrate diet; FENO, fenofibrate (100 mg.kg
-1
); 
Av, Aloe vera (300 mg.kg
-1
). The data in Figure 3.6 shows that there were no significant 
(p>0.05) differences observed in the hepatic glycogen content of treated rats. Data is presented 
as mean ± SEM. n=10 per group except NRC + FENO where n= 9
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CHAPTER FOUR- DISCUSSION
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The present study investigated the effects of a crude whole leaf Aloe vera extract on a diet-
induced metabolic dysfunction. The aim of this study was to establish an animal-based model 
of diet-induced metabolic dysfunction and explore whether administration of Aloe vera would 
delay the development of metabolic dysfunction as measured by some makers of metabolic 
dysfunction i.e. circulating metabolic substrates, insulin levels, and visceral obesity. The 
possible adverse effects of the extracts were also assessed by determining markers of liver 
function and histology. Fenofibrate was used as a positive control. 
The high carbohydrate diet led to a significant increase in body mass gain and manifestation of 
central obesity i.e. increased visceral fat mass. The increase in body mass gain observed in rats 
fed a high carbohydrate diet in the present study is in line with a previous study by Majane et 
al, (2009) who observed that adult rats assigned to a similar diet for five months showed an 
increased body mass gain in comparison to rats on a normal diet.  
In the present study, Aloe vera did not prevent the high carbohydrate diet-induced increase in 
body mass, which fenofibrate administration was able to prevent. Studies have shown that 
fenofibrate significantly reduced body mass in animal models of genetic diet-induced increase 
in body mass (Carmona et al., 2005).   
There was a significant increase in the mass of visceral fat of rats fed a high carbohydrate diet 
in comparison with the control. Fenofibrate administration prevented the increase in visceral 
fat mass. However, Aloe vera administration did not significantly prevent the diet-induced 
increase in visceral fat mass. My findings with Aloe vera are in contrast to previous studies 
using other animal models of metabolic dysfunction which have shown that Aloe vera-derived 
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phytosterols prevented the increase in the visceral fat mass (Misawa et al., 2008) in diabetic 
Zucker fat rats.  The increase in visceral fat might have contributed to the increased body mass 
in rats fed a high carbohydrate diet. Excess consumption of carbohydrates is associated with 
an increased visceral obesity (Slyper, 2004). Dietary carbohydrates are stored as glycogen in 
the liver, however, when glycogen storage is at a maximum, the only pathway for storage of 
glucose is the conversion into fats.  Excess fats then accumulate in the abdominal adipose 
tissue hence causing visceral obesity (Flatt, 1970).   
Changes in body mass may be influenced by several factors such as hydration status and 
prandial state therefore body mass is unreliable measurement for growth (Yin et al., 1982). 
The tibial length has been used in several studies as a more accurate indicator of linear growth 
(Eshet et al., 2004). To further explore the effects of Aloe vera on growth, I investigated the 
effects of Aloe vera on tibial length and mass. The tibial masses and lengths were not 
significantly affected by the exposure to the different treatments and diets. However, this is in 
contrast to previous studies which have shown that oral administration of Aloe vera resulted in 
an increase in tibial length, which the authors suggested could have resulted from an increase 
in metaphyseal bone tissue (Cho et al., 2001). 
Several studies show that a high intake of carbohydrate plays a major role in the development 
of increased visceral fat and abdominal obesity, which can lead to the development of insulin 
resistance (Basciano et al., 2005). I further investigated the adverse effect of exposure to the 
high carbohydrate diet and increased abdominal obesity by performing an oral glucose 
tolerance test, which is an index for insulin resistance (Loxman et al., 2007: Muellenbach, 
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2009) and can reveal a pre-diabetic state. Despite the diet-induced increased visceral adiposity, 
there were no abnormalities observed in the oral glucose tolerance indicating that the rats were 
not in a pre-diabetic state. Plasma insulin levels, as well as the homeostasis model assessment 
od insulin resistance were not affected by the different treatments. The precise mechanism of 
the high carbohydrate diet in the induction of insulin resistance is not well understood, 
however many animal studies have examined the genetic modification in the context of diet-
induced metabolic dysfunction (Buettner et al., 2006).  
The present study showed that long-term Aloe vera administration had no significant effect on 
fasting blood glucose levels. Previous studies in diabetic patients administration of  Aloe vera 
decreased blood glucose levels (Agarwal, 1985). In addition Ghannam et al. (1986) found that 
there were hypoglycemic agents present in Aloe vera that lowered blood glucose in Alloxan-
diabetic mice.  
The results obtained from this study also showed no significant differences between the 
fasting levels of circulating triglycerides of the rats in the different treatment groups. Several 
studies have shown that diets rich in carbohydrates may cause elevated triglycerides levels 
(Parks, 2002). Aloe vera has been shown to lower fasting triglycerides levels in rat models of 
streptozotocin-induced diabetes (Rajasekaran, 2004). Fenofibrate which I used as a positive 
control agent also did not significantly affect fasting triglyceride concentrations in my study. 
Chaput et al. (2000) found that fenofibrate did not only reduce body weight but it also resulted 
in the reduction of circulating triglycerides in (fa/fa) fatty Zucker rats and db/db mice.   
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The liver is one of the largest organs in the body that serves as a metabolic powerhouse for the 
processing of nutrients, absorption of lipids and glycogen storage to maintain energy levels 
(Koeppen and Stanton, 2008).  Several studies have shown that hepatic lipid and glycogen 
content are affected by dietary treatment (Weigand et al., 1980). There were no significant 
differences observed in fasting hepatic lipid and glycogen storage of all the treatment groups. 
Research has shown that starvation may decrease lipid composition and glycogen (Weigand et 
al., 1980). Therefore, it can be speculated that the non-significant differences in hepatic lipid 
content and glycogen content may have been due to fasting the animals which could have 
depleted the hepatic lipid and glycogen content in rats fed a high carbohydrate diet to control 
levels in my study. Thus, future studies should be done to assess the levels of the metabolic 
substrates in non-fasted animals. 
 
In the present study, I observed a distinct liver enlargement in rats administered fenofibrate, 
but the hepatomegally was without any signs of hepatic steatosis. These observations were in 
line with previous studies where it was observed that long-term administration with the PPAR-
α agonist induces hepatomegally (Hong et al., 2007). So although in my study fenofibrate 
administration from an early age of the rats prevented the diet-induced increase in visceral 
adiposity, which might be medically beneficial, the side effects need to be taken into 
consideration. 
To further investigate the potential hepatotoxic effects of the treatments, I investigated 
markers of liver function (ALP, ALT, TBIL and GGT). The liver has a number of functions, 
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including metabolism and detoxification of several substances in the body. Since the liver cells 
are exposed to toxins, they are therefore at risk of damage (Gaskill et al., 2004).  Alanine 
aminotransferase (ALT) is an enzyme present in hepatocytes. When hepatocytes are damaged, 
the cells leak this enzyme into the blood. ALT is therefore useful as a marker for liver damage. 
There are several isoenzymes of Alkaline phosphatase (ALP) found in different tissues. ALP 
is an enzyme in the cells lining the biliary ducts of the liver. ALP levels in plasma rise with 
large bile duct obstruction. ALP is also present in bone so it is higher in growing animals as 
their bones are being remodeled (Nyblom et al., 2006). The GIT also produces ALP in rats 
(Zafar et al., 2009). There were no significant differences in the circulating concentrations of 
ALT in different groups of rats; these results suggest that there was no liver damage. 
However, the levels of alkaline phosphatase were increased only in the group receiving a 
normal rat chow and fenofibrate, but not in the group receiving a high carbohydrate diet and 
fenofibrate. Previous studies suggest that the increase in circulating ALP concentrations 
following fenofibrate treatment is not considered to be clinically significant (Dohmen et al., 
2005). Some of the serum ALP may come from the duodenal mucosa which contain two 
isoforms of the enzyme (Iwao et al., 1987; Koyama et al.,1987). Concentrations of total 
bilirubin were reduced in the group fed with normal rat chow and Aloe vera. However, in 
previous studies, the total bilirubin levels of rats treated with Aloe vera were not affected when 
compared to the control group (Saritha and Anilakumar, 2010).   Due to unavailability of 
equipment, it was not possible to identify the specific isoforms present in the rats in my study.  
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The principal role of the gastrointestinal tract (GIT) is to digest and absorb food, therefore 
apart from nutrients, the GIT is also exposed to ingested bacteria and other potentially harmful 
substances. Thus, the GIT has to adapt to various dietary changes (Yegani and Korver. 2008). 
The gastrointestinal tract therefore undergoes extensive structural and functional changes such 
as an alteration of the small intestinal villi and crypts (Traber and Silberg, 1996) and 
absorption capacity (Van Beers et al., 1998). Hence, evaluation of morphological changes can 
be used in the diagnosis and assessment of intestinal pathology (Weser and Tawil. 1976).  
In this present study, it was found that no significant changes occurred in the gross 
morphometry of the large intestine, caecum and the stomach other than the small intestine. 
However, the relative mass of the large intestine was reduced in rats on the high carbohydrate 
diet alone. This could be attributable to a possible lower level of fibre in the HCD. Fibre is 
important for the development of the large intestine (Eastwood, 1992). In a study in which 
suckling rats were administered Aloe vera extracts they found an increase in caecal mass 
(Beya et al., 2012). The presence of osmotically active or fermentable substances that are not 
absorbed from the small intestine may affect the GIT flora and influence caecum weight 
(Baltrop and Brueton, 1990). The increased large intestine mass could thus have been due to 
the presence of complex carbohydrates in the Aloe extracts resulting in the development of the 
flora which affects the production of volatile fatty acids and improved digestibility in rats 
(Reddy, 1971). It is noteworthy as well that there was no reduction in mass of the large 
intestine in rats fed the HCD and fenofibrate. The mass of the small intestine of rats fed 
normal rat chow and fenofibrate was also significantly increased but not in the other groups. 
The mechanisms underlying these effects of fenofibrate require further investigation.  
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I further investigated the possibility of micropathology of the small intestines; the intestinal 
morphology appeared to be normal. There were no differences in the villus heights between 
the groups. Although the morphology of the small intestines was not affected, the function of 
the GIT could have been affected, hence further studies should investigate the function of the 
small intestine to evaluate its absorptive and secretory capacity. 
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CHAPTER FIVE- CONCLUSION AND 
RECOMENDATIONS 
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 Aloe vera has been used for many decades. The present study has shown that weaning rats 
onto a high carbohydrate diet and feeding them the diet for 20 weeks resulted in the 
development of visceral obesity without altering the glucose tolerance, metabolic substrates 
and morphology. The animal model used thus did not result in the full development of 
metabolic syndrome. Other studies have generally used adult animals at the commencement of 
their studies, a period at which the rats have past the rapid growth phase. My use of young 
growing animals could have resulted in most of the dietary nutrients being channeled into 
rapid growth and hence the lack of excessive obesity. A longer feeding period would be 
recommended for future studies. The findings from the present study showed that the 
administration of fenofibrate prevented the high carbohydrate diet-induced visceral obesity 
whereas treatment with the Aloe vera leaf preparation was ineffective. However, the treatment 
with fenofibrate from an early age resulted in hepatomegally, the long-term functional 
significance of which requires further investigation. 
The present study involved the use of a crude leaf preparation; future studies should be 
conducted to compare the effect of a crude leaf and gel extract to evaluate their relative 
effectiveness. Future research should also be conducted to isolate the active constituents of the 
plant to provide a better understanding of its phytochemicals and the positive effects that have 
been noted by others.  
Although the findings in this study may assist in filling gaps on the effect of Aloe vera on diet-
induced metabolic dysfunction in growing children, the study has some limitations. My results 
suggest that Aloe vera administration at 300 mg.kg
-1  
through gelatine cubes did not have a 
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significant effect, perhaps for future studies it would be a good idea to change the method of 
administration as the gelatine cubes may have also had an effect on the activity on the 
constituents of Aloe vera. 
Understanding the liver metabolic gene profile as the liver plays a major role in metabolism 
would be interesting. Therefore, for future studies it would be worthwhile to measure gene and 
protein expression. 
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